 Bloomberg
Shares of Chiron Corp., the world's second-biggest seller of influenza vaccines, fell as much as 9.5 percent after saying it would delay shipments of its Fluvirin flu shots until October because of a possible product flaw.
Most of the product will reach the market about a month behind schedule, John Vavricka, Chiron's vice president of commercial operations for North America, said in an interview yesterday. The company will deliver 46 million to 48 million Fluvirin doses to the U.S., short of the 50 million planned.
More...
|
